The company’s breakthrough Point-of-Care Blood Testing is revolutionizing how quickly clinicians can evaluate a patient’s clotting ability.
HemoSonics, a pioneering leader in acute bleeding management, has been named Best Medical Device Company at the Triangle Business Journal’s 2025 Life Sciences Awards.
The company’s flagship innovation, the Quantra Hemostasis System, is reshaping patient care with fast, comprehensive blood coagulation analysis. It delivers results in under 15 minutes at the point of care or in lab settings.
HemoSonics’ Quantra Hemostasis System stands out for its speed, accuracy, and clinical impact. Designed to guide treatment decisions in real time, especially during critical procedures such as cardiovascular surgery and liver transplants. The system provides clear, actionable insights into a patient’s coagulation status.
A Diagnostic Breakthrough in Hemostasis Management
The Quantra Hemostasis Analyzer, together with its QPlus® and QStat® cartridges, employs proprietary SEER Sonorheometry (Sonic Estimation of Elasticity via Resonance), a cutting-edge ultrasound-based technology that measures the viscoelastic properties of whole blood. This allows clinicians to evaluate a patient’s clotting ability quickly and comprehensively.
Traditional lab-based coagulation tests can take up to an hour or more to return results — a critical delay when managing acute bleeding. In contrast, the Quantra System delivers a complete hemostasis profile in under 15 minutes.
This enables clinicians to make faster, better-informed decisions, minimize unnecessary transfusions, and ultimately save lives.
Driving Innovation in Point-of-Care Blood Testing
“Innovation is at the heart of what we do at HemoSonics,” said Bob Roda, President and CEO of HemoSonics. “We are honored to receive this award and to be recognized among fellow Research Triangle Park companies that are transforming the future of healthcare.”
The Quantra Hemostasis System has been FDA-cleared for use in:
- Cardiovascular surgery
- Trauma
- Liver transplantation
- Major orthopedic surgery
Its growing adoption is fueled by its ease of use, minimal maintenance needs, and ability to standardize bleeding management protocols across healthcare systems. The analyzer’s intuitive design allows both laboratory professionals and surgical teams to operate it efficiently, improving operational workflows and reducing reliance on centralized testing facilities.
Award-Winning Technology with Global Recognition
In addition to its 2025 win from the Triangle Business Journal, the Quantra System has received a series of prestigious accolades, underscoring its role as a leader in medical device innovation:
- 2024 TIME Best Inventions
- 2024 Fast Company Most Innovative Companies (Medtech)
- 2024 Edison Awards (Point-of-Care and Therapeutic Solutions)
- 2024 Deloitte Fast 500, recognizing North America’s fastest-growing tech companies
These honors reflect the system’s significant contribution to advancing point-of-care diagnostics and empowering frontline healthcare professionals with real-time clinical intelligence.
Supporting North Carolina’s Thriving Life Sciences Ecosystem
HemoSonics is headquartered in Durham, North Carolina, at the heart of the Research Triangle Park (RTP) — a region nationally recognized for its concentration of biotech, pharma, diagnostics, and medical device firms. According to the North Carolina Biotechnology Center, the state is home to more than 840 life sciences companies, many of which are clustered in RTP.
The Triangle Business Journal’s Life The Science Awards spotlight leaders and innovators driving scientific discovery, product development and healthcare advancements in the region. HemoSonics’ inclusion on this distinguished list reflects not only its innovation but also its contribution to the state’s growing reputation as a global hub for medical technology.
Better Care Through Better Coagulation Testing
The clinical advantages of the Quantra System are clear:
- Faster time-to-decision in high-stakes surgical settings
- Reduced blood product usage through more targeted transfusion strategies
- Improved patient safety and fewer post-operative complications
- Lower healthcare costs via operational efficiencies and standardized testing protocols
With bleeding-related complications among the leading causes of mortality in surgery and trauma, advanced viscoelastic testing like that provided by the Quantra System is not just a technical achievement — it’s a critical tool for improving outcomes and saving lives.
Looking Ahead: Setting the Standard for Hemostasis Diagnostics
As hospitals seek scalable solutions to enhance perioperative care, reduce costs, and support value-based care models, demand for rapid, reliable, and easy-to-use coagulation diagnostics is on the rise. The Quantra Hemostasis System is positioned to become the standard of care in bleeding management, from trauma centers to transplant units.
Through ongoing innovation and clinical collaboration, HemoSonics continues to push the boundaries of what’s possible in acute hemostasis management, reinforcing its mission to improve the way bleeding is diagnosed and treated — and to ultimately deliver better care for every patient.
